Companies ›Healthcare ›ZYBT.O

ZYBT.O — NASDAQ Diversified Pharmaceuticals

Zhengye Biotechnology Holding Ltd

$1,26

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

37,5M USD

P/E

—

EV / Rev

—

Div yield

—

Op margin

—

ROE

—

Net margin

—

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$0,81

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Zhengye Biotechnology Holding Ltd is a biotechnology company engaged in the research, development, and commercialization of biopharmaceutical products.

Business. Zhengye Biotechnology Holding Ltd (ZYBT.O) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the Healthcare sector, specifically focusing on product sales within the Pharmaceuticals industry. Headquarters and specific operating segment details are not provided in the available data. The company is primarily listed on the NASDAQ stock exchange.

Classification99 %

SectorHealth Care

Industry groupDiversified Pharmaceuticals

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership→

Geode Capital Management, L.L.C.

largest disclosed fund holder

Profitability

—

not yet wired

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning ZYBT.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to ZYBT.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Zhengye Biotechnology Holding Ltd (ZYBT.O) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the Healthcare sector, specifically focusing on product sales within the Pharmaceuticals industry. Headquarters and specific operating segment details are not provided in the available data. The company is primarily listed on the NASDAQ stock exchange.

Classification99 %

SectorHealth Care

Industry groupDiversified Pharmaceuticals

AI synthesis

GENERATED

Zhengye Biotechnology has a market capitalization of 28.24 million USD, based on a market price of 0.95 USD per share and 29.73 million shares outstanding. The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

The company's profitability and return metrics are not available for comparison with industry medians, as no financial performance data is disclosed in the valuation snapshot. This lack of data limits the ability to assess its performance relative to peers in the Pharmaceuticals industry.

Zhengye Biotechnology's revenue concentration and geographic exposure are not disclosed in the available data. The company's segmental breakdown is also not available, which limits the ability to assess its diversification across product lines or regions.

The company's growth trajectory is not quantifiable due to the absence of historical revenue data and forward-looking guidance in the available documents. No numeric deltas or outlooks are provided for the current or next fiscal year.

The company's risk profile is marked by low dilution potential, with no significant dilution sources identified in the available documents. However, the absence of balance-sheet data and going-concern language raises concerns about its financial stability.

No recent events, such as filings or transcripts, are disclosed in the available data, which limits the ability to assess the company's recent operational or strategic developments.

Key takeaways

Zhengye Biotechnology has a small market capitalization of 28.24 million USD, indicating limited investor interest or market presence.
The company's financial performance and return metrics are not disclosed, making it difficult to assess its profitability relative to industry peers.
No segmental or geographic revenue breakdown is available, limiting visibility into the company's diversification and exposure.
The company's liquidity risk could not be assessed due to the absence of balance-sheet data and no going-concern language in source documents.
No recent events or strategic developments are disclosed, which limits the ability to evaluate the company's current direction.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation FY

Market price

$1,26

Market cap

$28.2M

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

—

Current ratioⓘ

—

Debt / equityⓘ

—

ROAⓘ

—

ROEⓘ

—

Cash conversionⓘ

—

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs ZYBT · multiples and returns

MCK—

Mckesson Corp

$827,14

102,6B USD

P/E

21,2x

— vs self

Div yield

0,4 %

— vs self

ROE

-219,2 %

— vs self

COR—

Cencora Inc

$308,37

60,2B USD

P/E

36,4x

— vs self

Div yield

0,8 %

— vs self

ROE

45,7 %

— vs self

CAH—

Cardinal Health Inc

$235,60

57,0B USD

P/E

36,7x

— vs self

Div yield

0,9 %

— vs self

ROE

-55,9 %

— vs self

DB—

DB.V

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

REGN—

REGENERON PHARMACEUTICALS, INC.

$757,99

81,0B USD

P/E

15,5x

— vs self

Div yield

—

— vs self

ROE

14,2 %

— vs self

BIIB—

BIOGEN INC.

$201,74

29,6B USD

P/E

21,3x

— vs self

Div yield

—

— vs self

ROE

7,5 %

— vs self

ZTS—

Zoetis Inc

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

GRFS—

Grifols SA

$7,86

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskUnknown

Benchmarks vs cohort

No cohort benchmark data available for this issuer yet.

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted

Source documents

Zhengye Biotechnology Holding Ltd Market data — financials · 2026-05-30

Ownership & reference

Top holders

Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M

Insider activity

— missing data

Short positioning

57.4Kshares short+31.8% vs prior

1days to cover

52.4%short of daily vol

247fails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

ZYBT.OCanonical

NASDAQ · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskUnknown

Evidence & claims

From filings & derived data

Gross margin (FY 2025-12-31): 20.5%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): -547.8%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): 46.9%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): -34.8%Derived (calculated)
Current ratio (FY 2025-12-31): 1.14xDerived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): -7.6%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -3.7%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -8.2%Derived (calculated)
Debt-to-equity (FY 2025-12-31): 0.52xDerived (calculated)
Capex (YoY) (2025-12-31 vs 2024-12-31): -92.3%Derived (calculated)
Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 1.6%Derived (calculated)
Gross profit (YoY) (2025-12-31 vs 2024-12-31): -72.7%Derived (calculated)
Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -16.9%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): -744.0%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -66.0%Derived (calculated)
Net margin (FY 2025-12-31): -60.0%Derived (calculated)
Return on equity (FY 2025-12-31): -27.9%Derived (calculated)
Return on assets (FY 2025-12-31): -16.0%Derived (calculated)
Operating cash flow (annual): USD 1.91MSEC XBRL filing
Total assets (annual): USD 62.41MSEC XBRL filing
Gross profit (annual): USD 3.41MSEC XBRL filing
Pre-tax income (annual): USD -10.28MSEC XBRL filing
Total operating expenses (annual): USD 13.5MSEC XBRL filing
Long-term debt (annual): USD 1.37MSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-06-04FILINGREPORT OF FOREIGN PRIVATE ISSUER →

2026-04-28FILINGANNUAL REPORT →

2026-03-25FILINGREPORT OF FOREIGN PRIVATE ISSUER →

2026-03-02FILINGREPORT OF FOREIGN PRIVATE ISSUER →

2026-02-23FILINGREPORT OF FOREIGN PRIVATE ISSUER →

2025-12-12FILINGREPORT OF FOREIGN PRIVATE ISSUER →

2025-07-03FILINGANNUAL REPORT →

2025-05-23FILINGREPORT OF FOREIGN PRIVATE ISSUER →

2025-04-03FILINGREPORT OF FOREIGN PRIVATE ISSUER →

2025-03-06FILINGREPORT OF FOREIGN PRIVATE ISSUER →

2025-01-14FILINGREPORT OF FOREIGN PRIVATE ISSUER →

2025-01-08FILINGREPORT OF FOREIGN PRIVATE ISSUER →

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread